Lobeglitazone
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Lobeglitazone: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Lobeglitazone is a thiazolidinedione (TZD)-class PPAR-γ agonist known for type 2 diabetes management; detailed original-indication and MOA fields are not populated in this evidence pack. The TxGNN model predicts it may be relevant to Focal Stiff Limb Syndrome, but this is a pure knowledge-graph prediction (L5) with zero clinical trials and zero publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (known TZD/PPAR-γ agonist class; not captured in structured Taiwan license data) |
| Predicted New Indication | Focal Stiff Limb Syndrome |
| TxGNN Prediction Score | 99.17% |
| Evidence Level | L5 |
| Taiwan Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Lobeglitazone is part of the thiazolidinedione (TZD) class of PPAR-γ agonists, and its efficacy in type 2 diabetes has been proven; mechanistically it is being proposed as possibly applicable to focal stiff limb syndrome.
Focal stiff limb syndrome is considered a localized variant of stiff person syndrome, an autoimmune neuromuscular disorder. The proposed mechanistic link relies on PPAR-γ activation’s known partial anti-inflammatory/immunomodulatory effects, which could theoretically intersect with the autoimmune component of this disease.
However, this connection is explicitly flagged in the source evidence as indirect and unvalidated — there is no established evidence that TZD-class drugs affect GABAergic neurotransmission or autoimmune neuromuscular excitability pathways. The high TxGNN score (99.17%) reflects proximity within the knowledge graph rather than a mechanistically or clinically validated relationship, and is unsupported by any clinical trial or literature evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Lobeglitazone currently has no marketing authorization on file in Taiwan (0 registrations, status: Not marketed/Not Marketed). No product, dosage form, or approved indication data is available.
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and DDI data are currently unavailable/pending TFDA label acquisition — this is flagged as a Blocking data gap [DG001] for safety assessment.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate rests entirely on a knowledge-graph score (L5) with no supporting clinical trials or literature, and the proposed mechanistic link between PPAR-γ agonism and an autoimmune neuromuscular disorder is explicitly characterized as indirect and unvalidated. The drug is also not marketed in Taiwan, and other top-ranked predictions for this molecule (classic stiff person syndrome, thiamine-responsive dysfunction syndrome, opsismodysplasia) show the same L5/Hold pattern with equally tenuous mechanistic rationale — suggesting these high scores may largely reflect knowledge-graph co-occurrence rather than genuine repurposing signal.
To proceed, the following is needed:
- TFDA label data (warnings/contraindications) to clear the blocking safety data gap (DG001)
- Confirmed mechanism of action (DG001/DG002) to properly evaluate mechanistic plausibility
- Preclinical or case-level evidence linking PPAR-γ agonism to autoimmune/neuromuscular excitability disorders
- Any real-world DDI data, since the current DDI query returned no results
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.